Recurrent tuberculosis in Denmark: Relapse vs. re-infection

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 4, 2010, Pages 447-453

  Bang, Didi ^a   Andersen, A B ^b   Thomsen, V O ^a   Lillebaek, T ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Epidemiology; Genotype; RFLP; Treatment outcome; Tuberculosis recurrence

Indexed keywords

ADULT; ARTICLE; BACTERIUM ISOLATE; COHORT ANALYSIS; DENMARK; FEMALE; GENE INSERTION; GENE SEQUENCE; GENOTYPE; HUMAN; INCIDENCE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; COHORT STUDIES; DENMARK; DNA, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POPULATION SURVEILLANCE; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 77950307302     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis control - epidemiology, strategy, financing. WHO report 2009. WHO/ HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
2. EPI-NEWS. National surveillance of communicable diseases, tuberculosis. Copenhagen, Denmark: Department of Epidemiology, Statens Serum Institut, 1992-2005.
3. Dobler C C, Marks G B, Simpson S E, Crawford A B. Recurrence of tuberculosis at a Sydney chest clinic between 1994 and 2006: reactivation or re-infection? Med J Aust 2008; 188: 153-155.
4. Cacho J, Perez M A, Cano I, et al. Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. Eur Respir J 2007; 30: 333-337.
5. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous re-infection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39: 2213-2218.
6. Caminero J A, Pena M J, Campos-Herrero M I, et al. Exogenous re-infection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-720.
7. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and re-infection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
8. Fine P E, Small P M. Exogenous re-infection in tuberculosis. N Engl J Med 1999; 341: 1226-1227.
9. Cox H S, Morrow M, Deutschmann P W. Long-term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008; 336: 484-487.
10. De Boer A S, Borgdorff M W, Vynnycky E, Sebek M M, van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis 2003; 7: 145-152.
11. El Sahly H M, Wright J A, Soini H, et al. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis 2004; 8: 333-340.
12. Chiang C Y, Riley L W. Exogenous re-infection in tuberculosis. Lancet Infect Dis 2005; 5: 629-636.
13. Jasmer R M, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or re-infection? Am J Respir Crit Care Med 2004; 170: 1360-1366.
14. Kok-Jensen A, Thuesen Pedersen J, Taudorf E, Viskum K. The national tuberculosis program and proposed clinical management of tuberculosis. Consensus report no. 11. Copenhagen, Denmark: Danish Lung Association, Danish Medical Association, 2001.
15. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5: 213-215.
16. Vijdea R, Stegger M, Sosnovskaja A, Andersen A B, Thomsen V O, Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008; 27: 1079-1086.
17. Van Rie A, Warren R, Richardson M, et al. Exogenous re-infection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
18. Van Embden J D, Cave M D, Crawford J T, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409.
19. Garcia D V, Marin M, Hernangomez S, et al. Tuberculosis recurrences: re-infection plays a role in a population whose clinical/epidemiological characteristics do not favour re-infection. Arch Intern Med 2002; 162: 1873-1879.
20. Lambert M L, Hasker E, van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or re-infection? Lancet Infect Dis 2003; 3: 282-287.
21. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
22. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study. Am Rev Respir Dis 1984; 129: 921-928.
23. Chang K C, Leung C C, Yew W W, Chan S L, Tam C M. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158.
24. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
25. Panjabi R, Comstock G W, Golub J E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828-837.
26. Nettles R E, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736.
27. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
28. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
29. Heldal E, Docker H, Caugant D A, Tverdal A. Pulmonary tuberculosis in Norwegian patients. The role of reactivation, re-infection and primary infection assessed by previous mass screening data and restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 2000; 4: 300-307.
30. Verver S, Warren R M, Beyers N, et al. Rate of re-infection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
31. Wang J Y, Lee L N, Lai H C, et al. Prediction of the tuberculosis re-infection proportion from the local incidence. J Infect Dis 2007; 196: 281-288.
32. Van Helden P D, Warren R M, Uys P. Predicting re-infection in tuberculosis. J Infect Dis 2008; 197: 172-173.
33. Warren R M, Victor T C, Streicher E M, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004; 169: 610-614.
34. Lillebaek T, Poulsen S, Kok-Jensen A. Tuberculosis treatment in Denmark: treatment outcome for all Danish patients in 1992. Int J Tuberc Lung Dis 1999; 3: 603-612.